The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Market Size Of The Uterine Fibroids Treatment Market In 2026 And What Value Is Projected For 2030?
The uterine fibroids treatment market has experienced substantial growth in recent times. This market is projected to expand from $4.43 billion in 2025 to reach $4.85 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.7%. Historically, this expansion can be attributed to several factors including improved awareness regarding uterine fibroid symptoms, the widespread availability of surgical treatment options, an increase in gynecological care facilities, higher diagnosis rates achieved through imaging techniques, and the overall development of women’s healthcare services.
The uterine fibroids treatment market size is projected to experience robust expansion over the coming years, with an anticipated rise to $7.08 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.9%. This projected growth during the forecast period can be attributed to factors such as the increasing adoption of non-surgical treatment alternatives, a rising demand for fertility-preserving therapies, the expansion of outpatient gynecological procedures, growing investment in women’s health research, and the increasing use of image-guided therapies. Major trends expected in the forecast period include the increasing adoption of minimally invasive treatment procedures, a growing use of hormonal and non-hormonal therapies, a rising preference for uterus-preserving treatments, the expansion of advanced imaging-guided interventions, and enhanced patient-centric treatment planning.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10766&type=smp
What Key Drivers Are Influencing The Growth Of The Uterine Fibroids Treatment Market?
The significant prevalence of uterine fibroids among women is projected to propel the expansion of the uterine fibroids treatment market moving forward. Uterine fibroids are characterized as non-cancerous growths that develop within the uterus and can lead to symptoms such as extensive menstrual bleeding, pelvic discomfort, and pressure on the bladder or intestines. Treatment for uterine fibroids works by blocking the production of estrogen and progesterone, thereby stopping menstruation and alleviating anemia. For instance, in September 2024, according to Oxford Academic, a UK-based publisher of the journal Human Reproduction, approximately 7.3% of Australian women had received a diagnosis of uterine fibroids by age 45–49, with the highest age-specific incidence noted among women aged 40–44 (5.0 new cases per 1,000 person-years). Consequently, the substantial prevalence of uterine fibroids among women globally is driving the growth of the uterine fibroids treatment market.
What Are The Key Segments Of The Uterine Fibroids Treatment Market?
The uterine fibroids treatment market covered in this report is segmented –
1) By Type: Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids
2) By Treatment Type: Hormone Therapy, Androgens, Gonadotropin-Releasing Hormone Antagonists, Uterine Artery Embolization, Myomectomy, Hysterectomy
3) By End-Users: Hospitals, Ambulatory Surgical Centers, Other End users
Subsegments:
1) By Subserosal Fibroids: Pedunculated Subserosal Fibroids, Non-Pedunculated Subserosal Fibroids
2) By Intramural Fibroids: Small Intramural Fibroids, Large Intramural Fibroids
3) By Submucosal Fibroids: Pedunculated Submucosal Fibroids, Non-Pedunculated Submucosal Fibroids
4) By Pedunculated Fibroids: Subserosal Pedunculated Fibroids, Submucosal Pedunculated Fibroids
What Major Market Trends Are Driving Changes In The Uterine Fibroids Treatment Market?
Leading companies within the uterine fibroid treatment market are embracing product innovations, including non-hormonal therapies and adaptable dosing solutions, to address diverse patient requirements and maintain a competitive advantage. Non-hormonal treatments for uterine fibroids, such as GnRH receptor antagonists, operate by inhibiting gonadotropin-releasing hormone at pituitary receptors, thereby diminishing estrogen production and relieving symptoms like heavy bleeding and pelvic pain. For instance, in September 2024, Kissei Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, introduced YSELTY, a treatment for uterine fibroids, marking a significant development in women’s healthcare. YSELTY provides a non-hormonal treatment alternative, offering flexible dosing options customized to individual patient needs, particularly for those with severe fibroid symptoms. As a GnRH receptor antagonist, YSELTY works to reduce estrogen production by inhibiting gonadotropin-releasing hormone at its pituitary receptors, effectively alleviating symptoms such as bleeding and pain.
Who Are The Leading Companies Operating In The Uterine Fibroids Treatment Market?
Major companies operating in the uterine fibroids treatment market are Gynesonics Inc., Medtronic plc, Boston Scientific Corporation, Karl Storz GmbH, Pfizer Inc., Abbvie Inc., Richard Wolf GmbH, CooperSurgical Inc., Olympus Corporation, Myovant Sciences GmbH, Insightec Ltd., Hologic Inc., Obseva SA, Eli Lilly and Company, GlaxoSmithKline plc, Stryker Corporation, Smith & Nephew plc, Minerva Surgical Inc., Ethicon Inc., Cook Medical LLC, C.R. Bard Inc., Biomerics LLC, Visionsense Corp., Halt Medical Inc., Acessa Health Inc., Blue Endo, LiNA Medical ApS, Merit Medical Systems Inc., Allergan plc, Astellas Pharma Inc.
Read the full uterine fibroids treatment market report here:
https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report
Which Region Is Expected To Register The Fastest Growth In The Uterine Fibroids Treatment Market?
North America was the largest region in the uterine fibroids treatment market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the uterine fibroids treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Uterine Fibroids Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=10766&type=smp
Browse Through More Reports Similar to the Global Uterine Fibroids Treatment Market 2026, By The Business Research Company
Uterine Fibroids Treatment Global Market Report
https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report
Uterine Fibroid Embolization Device Global Market Report
Endometrial Cancer Treatment Global Market Report
https://www.thebusinessresearchcompany.com/report/endometrial-cancer-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model